---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-001938"
form_type: "8-K"
ticker: "AVR"
cik: "0002011514"
company_name: "Anteris Technologies Global Corp."
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T09:01:17.512238+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Anteris raises ~$320M via public offering and Medtronic PIPE for DurAVR THV trial

## Summary
- Public offering of 40M shares at $5.75 (including full over-allotment); gross proceeds ~$230M.
- Medtronic subsidiary invests $90M via PIPE at same $5.75 price; gets board observer and participation rights.
- Proceeds to fund PARADIGM pivotal trial of DurAVR THV, expand manufacturing, and v2vmedtech R&D.
- Offering and PIPE expected to close Jan 22, 2026; officers/directors subject to 90-day lock-up.
- Medtronic's shares subject to transfer restrictions until May 2027 and volume limits through Jan 2029.

## SEC filing metadata
- accession: 0001140361-26-001938
- form_type: 8-K
- ticker: AVR
- cik: 0002011514
- company_name: Anteris Technologies Global Corp.
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2011514/000114036126001938/0001140361-26-001938-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2011514/000114036126001938/ny20062007x7_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-001938
- JSON: https://secwatch.observer/filing/0001140361-26-001938.json
- Plain text: https://secwatch.observer/filing/0001140361-26-001938.txt

## Key facts
- Material Agreements
  Anteris Technologies Global Corp. entered into Underwriting Agreement with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein valued at approximately $320 million (effective 2026-01-20).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein
  - Value: approximately $320 million
  - Effective: 2026-01-20
  source text: On January 20, 2026, Anteris Technologies Global Corp. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Barclays Capital Inc., Wells Fargo Securities, LLC and Cantor Fitzgerald & Co., acting as representatives of the several underwriters named therein (the “Underwriters”), pursuant to which the Company agreed to issue and sell (the “Offering”) 34,782,609 shares (the “Firm Stock”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a price to the public of $5.75 per share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2011514/000114036126001938/0001140361-26-001938-index.htm
- Material Agreements
  Anteris Technologies Global Corp. entered into Purchase Agreement with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc valued at approximately $90.0 million (effective 2026-01-20).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc
  - Value: approximately $90.0 million
  - Effective: 2026-01-20
  source text: On January 20, 2026, the Company entered into a stock purchase agreement (the “Purchase Agreement”) with Covidien Group S.à r.l., a wholly owned subsidiary of Medtronic plc (the “Investor”), pursuant to which the Company agreed to issue and sell (the “Private Placement”) to the Investor 15,652,173 shares of Common Stock of the Company (the “PIPE Shares”) at a purchase price of $5.75 per PIPE Share.
  evidence_url: https://www.sec.gov/Archives/edgar/data/2011514/000114036126001938/0001140361-26-001938-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.